Europe
There is some evidence that COVID-19 infection might be linked to an increase in diabetes, particularly Type 1 diabetes, which is an autoimmune disease most commonly diagnosed in children.
After reviewing the trial’s Independent Data Monitoring Committee, the EMPA-KIDNEY trial announced it would stop early as it met prespecified criteria for positive efficacy.
More pharmaceutical companies are joining to put economic pressure on Russia by suspending some or all operations within that country following the invasion of Ukraine.
Sanofi secured a €300 million investment to advance the development of a subcutaneous formulation of Sarclisa, an anti-CD38 antibody for patients with multiple myeloma.
Many countries around the world that appeared to have kicked COVID-19, are reporting surges, largely the result of the so-called “stealth” Omicron variant, BA.2, and more COVID news.
The drop in value has prompted MorphoSys to make drastic changes, such as discontinuing its U.S. operations and abandoning several pipeline projects.
The Orphazyme board of directors decided to cut 50% of its current global staff count after carefully considering its financial state.
Denali initiates dosing in Phase I/II frontotemporal dementia study. Intellia snags Orphan Drug Designation for experimental T cell receptor (TCR)-T cell therapy, NTLA-5001 in AML.
Researchers saw that programmed death ligand 1 on dendritic cells could control adaptive immune responses within adipose tissues to limit diet-induced obesity.
Morningside Ventures launched a new biotech company called Adiso Therapeutics, and thriving startup Scenic Biotech scooped up €28 million ($31 million) in funding.
PRESS RELEASES